We are thrilled to announce that we have established a meaningful, collaborative, strategic partnership with Cure Parkinson’s, the operating name of The Cure Parkinson’s Trust, a charity registered in the UK. Cure Parkinson’s share our vision of a world without Parkinson’s and are key drivers of international collaborations and funding of clinical trials that have the potential to slow, stop or reverse the progression of Parkinson’s. They established and continue to lead the International Linked Clinical Trials (iLCT) programme, a drug-repurposing initiative that prioritizes promising drugs for testing in clinical trials. The problem of Parkinson’s disease is truly a global one and the solution will come from strategic and collaborative coordination of global efforts to find a cure.
This partnership brings us into a global collective of organisations singularly and tirelessly focused on finding a cure for this insidious disease. Through it, we have the opportunity to multiply our own funds and leverage matched funding from partner organisations to accelerate clinical research and the process of getting new drugs approved for patients with Parkinson’s. The partnership with Cure Parkinson’s was a key first step in our rebranding, and we are hugely grateful to the fabulous team there for their welcoming enthusiasm in graciously allowing us to adopt our new name, Cure Parkinson’s NZ.
As part of this strategic partnership and in collaboration with other global partners of Cure Parkinson’s, we will have opportunities to co-fund global clinical trials of treatments with the potential to be game changers for people living with Parkinson’s disease (such as the phase 3 trial of ambroxol, a potential disease-modifying treatment, centred at University College London, which is getting underway in 2023). Importantly, any funds provided by Cure Parkinson’s NZ would effectively be at least tripled, owing to matched funding from partner organisations! This is the power of a strategic global network. We are on the look-out for a major donor (or a consortium of major donors) that would like to contribute to these important clinical trials, where outcomes and impact of donations can be measured and tracked. Imagine being a part of the funding group behind the clinical assessment and approval of the first drug to stop or slow Parkinson’s progression!! Please get in touch for a confidential conversation if you would like to learn more about these opportunities.